Jul 21, 2024, 11:23
Commercial interests appear to be influencing evidence standards for multi-cancer early detection tests
Dario Trapani, Medical Oncologist at European Institute of Oncology, shared a post by Benjamin Mazer, Assistant Professor of Pathology at Johns Hopkins University, on X:
“Commercials determinants of health are now being investigated and tacked based on a systematic strategy.
Cancer screening is now a big part of this problem.
See the recent WHO/Europe report from the NCD to learn more. ”
Quoting Benjamin Mazer‘s post:
“Commercial interests appear to be influencing evidence standards for multi-cancer early detection tests.”
Multicancer Early Detection Tests — Keeping a High Bar for Evidence of Benefit | NEJM
Authors: Hilary A. Robbins
Source: Dario Trapani/X and Benjamin Mazer/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43
Dec 3, 2024, 09:35